AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech's Zabopegdutide in Phase 2 MASH Trial
SINGAPORE and SEOUL, South Korea, June 18, 2026 /PRNewswire/ -- HistoIndex, a leader in AI-powered digital pathology solutions for fibrosis assessment, and D&D Pharmatech, today announced positive results from HistoIndex's AI-based quantitative...
HistoIndex Extends Access To Its MASH Diagnostic Offering Through New Partnerships In Texas And California
SINGAPORE, April 28, 2026 /PRNewswire/ -- HistoIndex, a pioneer in AI-driven digital pathology solutions for chronic liver disease, has announced the continued expansion of its commercial partnership network in the United States with the addition of...
HistoIndex Partners with Houston Research Institute to Expand Advanced MASH Diagnostic Services
SINGAPORE, Jan. 21, 2026 /PRNewswire/ -- HistoIndex, a pioneer in AI-driven digital pathology solutions for chronic liver disease, has announced a strategic partnership with Houston Research Institute (HRI). HRI is a leading research institute...
HistoIndex Secures SGD9 Million Investment to Drive Next Phase of Expansion
SINGAPORE, May 2, 2025 /PRNewswire/ -- HistoIndex, known for its groundbreaking biophotonic Second Harmonic Generation (SHG) technology and a pioneering leader in Artificial Intelligence (AI) digital pathology for the management of fibrotic...
A New Standard in Clinical Care for MASH Patients: HistoIndex Launches FibroSIGHT™
SINGAPORE, March 18, 2025 /PRNewswire/ -- HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of their first Laboratory Developed Test (LDT) FibroSIGHT™ – now available in...
BRIDGING CLINICAL RESEARCH AND CLINICAL CARE WITH AI-AIDING PATHOLOGISTS TOOL
SINGAPORE, Dec. 9, 2024 /PRNewswire/ -- A newly published collaborative study [ 1] in the Journal of Hepatology, featuring HistoIndex – a global leader in stain-free digital pathology solutions for managing fibrotic diseases – alongside Merck &...